# A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.

> **NCT00436241** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 45 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** capecitabine [Xeloda]

## Key facts

- **NCT ID:** NCT00436241
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436241, "A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00436241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*